The price of Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) shares last traded on Wall Street fell -16.76% to $2.98.
Based on available information, 1 analysts follow Salarius Pharmaceuticals Inc. (NASDAQ:SLRX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $125.00 and a low of $125.00, we find $125.00. Given the previous closing price of $3.58, this indicates a potential upside of 3391.62 percent. SLRX stock price is now 60.32% away from the 50-day moving average and -32.28% away from the 200-day moving average. The market capitalization of the company currently stands at $8.20M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $125.00 as their price target over the next twelve months.
With the price target of $3.80, Ladenburg Thalmann recently initiated with Buy rating for Salarius Pharmaceuticals Inc. (NASDAQ: SLRX).
In other news, Burleson Tess, Director bought 27,700 shares of the company’s stock on Jun 07. The stock was bought for $4,986 at an average price of $0.18. Upon completion of the transaction, the Director now directly owns 32,050 shares in the company, valued at $95509.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 07, Director Lieber Jonathan I bought 37,500 shares of the business’s stock. A total of $7,016 was incurred on buying the stock at an average price of $0.19. This leaves the insider owning 37,500 shares of the company worth $0.11 million. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SLRX stock. In total, there are 30 active investors with 16.30% ownership of the company’s stock.
A candlestick chart of Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) showed a price of $3.8900 on Friday morning. During the past 12 months, Salarius Pharmaceuticals Inc. has had a low of $1.07 and a high of $13.46. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.80, and a quick ratio of 5.80. The fifty day moving average price for SLRX is $1.8795 and a two-hundred day moving average price translates $4.3652 for the stock.
The latest earnings results from Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) was released for Jun, 2022.
Salarius Pharmaceuticals Inc.(SLRX) Company Profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
